YANTAI DONGCHENG PHARMACEUTICAL GROUP CO.,LTD.

Yantai Dongcheng Pharmaceutical Group Co.,Ltd.

002675

CNE100001DP5

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 23:00:00 16/07/2024 BST			5-day change	1st Jan Change
12.11 ^CNY	+0.83%		+2.71%	-33.93%

07-08	Dongcheng Biochemicals' Unit Gets Nod to Register Coronary Artery Disease Drug	MT
06-17	Yantai Dongcheng Pharmaceutical Group Co.,Ltd. Announces Final Dividend on A Shares for the Year 2023, Payable on 24 June 2024	CI

Yantai Dongcheng Pharmaceutical Group Co.,Ltd. announced that it has received CNY 349.999684 million in funding

January 06, 2022

On January 7, 2022, Yantai Dongcheng Pharmaceutical Group Co.,Ltd. closed the transaction. The company announced that it has received China Securities Regulatory Commission Administrative License Application Receipt (Acceptance No. 213594).

Latest news about Yantai Dongcheng Pharmaceutical Group Co.,Ltd.

Dongcheng Biochemicals' Unit Gets Nod to Register Coronary Artery Disease Drug	07-08	MT
Yantai Dongcheng Pharmaceutical Group Co.,Ltd. Announces Final Dividend on A Shares for the Year 2023, Payable on 24 June 2024	06-17	CI
Dongcheng Biochemicals' Unit Gets Nod to Trial Pancreatic Cancer Drug	05-27	MT
Yantai Dongcheng Pharmaceutical Group Co.,Ltd. Approves the Cash Dividend for the Year 2023	05-20	CI
US FDA Grants Clinical Trial Approval for Dongcheng Biochemicals' Injection	05-07	MT
Dongcheng Biochemicals' Unit Gets Nod to Trial Tumor Drug	04-29	MT
Yantai Dongcheng Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	04-26	CI
Yantai Dongcheng Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-26	CI
Dongcheng Biochemicals' Unit Gets Nod to Trial Tumor Drug in Singapore	04-11	MT
Dongcheng Pharmaceutical to Buy Liver Drug Rights from Affiliate for 85 Million Yuan	02-21	MT
Dongcheng Pharmaceutical Unit to Buy Rights to Tumor-Detecting Drug for 63 Million Yuan; Shares Up 10%	02-06	MT
Dongcheng Pharma's Singaporean Unit Gets FDA's Nod to Carry Out Trial on 68GaLNC1007 Injection	01-29	MT
Yantai Dongcheng Pharma Unit Secures License for Radioactive Cargo Transport	12-28	MT
Dongcheng Pharmaceutical Gets Nod to Trial Tumor Drug in China	12-05	MT
Yantai Dongcheng Pharmaceutical's Unit Ties Up With Chinese Physics Institute for Electron Accelerator Development	11-23	MT
Yantai Dongcheng Pharma Gets Nod to Trial Prostate Cancer Treatment in China	11-21	MT
Dongcheng Pharma Forms Medical Isotopes JV With Germany’s Eckert & Ziegler	11-15	MT
Qi Kang Medical Technology Co., Ltd. announced that it has received ?20 million in funding from Yantai Dongcheng Pharmaceutical Group Co.,Ltd.	11-13	CI
Dongcheng Biochemicals Unit Gets Nod to Trial Prostate Cancer Drug in Singapore	11-10	MT
Dongcheng Biochemicals' Unit Gets Nod to Market Dalteparin Sodium Injection	11-01	MT
Yantai Dongcheng Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	26/10/23	CI
Dongcheng Biochemicals Receives Good Manufacturing Practice Certificate from Germany	18/10/23	MT
Yantai Dongcheng Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23/08/23	CI
Yantai Dongcheng Pharma Registers Raw Material For Deep Vein Thrombosis Drug	01/08/23	MT
Yantai Dongcheng Pharma Registers Deep Vein Thrombosis Drug	13/07/23	MT

Chart Yantai Dongcheng Pharmaceutical Group Co.,Ltd.

Duration

Period

Chart Yantai Dongcheng Pharmaceutical Group Co.,Ltd.

More charts

Company Profile

Yantai Dongcheng Biochemicals Co., Ltd is a China-based company principally engaged in the research, development, manufacture and sales of medical drugs. The Companyâs main products are categorized into active pharmaceutical ingredients (APIs), nuclear medicines, chemical drugs and traditional Chinese medicines, which include heparin sodium APIs, chondroitin sulfate, preparation products, radionuclide drugs and others. The Company distributes its products in domestic market and to overseas markets.

Sector

Pharmaceuticals

Calendar

30/08/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Yantai Dongcheng Pharmaceutical Group Co.,Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

12.11 CNY

Average target price

17.8 CNY

Spread / Average Target

+46.99%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
YANTAI DONGCHENG PHARMACEUTICAL GROUP CO.,LTD.	-33.93%	1.36B
SUN PHARMACEUTICAL INDUSTRIES LTD.	+25.40%	45.35B
OTSUKA HOLDINGS CO., LTD.	+38.38%	24.34B
SANDOZ GROUP AG	+27.09%	16.51B
CIPLA LIMITED	+21.19%	14.6B
ZYDUS LIFESCIENCES LIMITED	+71.91%	14.27B
THE MEDICINES COMPANY	-0.05%	6.79B
ONO PHARMACEUTICAL CO., LTD.	-11.63%	6.57B
ASPEN PHARMACARE HOLDINGS LIMITED	+13.07%	5.76B
STADA ARZNEIMITTEL	-8.87%	5.73B

Generic Pharmaceuticals